Joshua McCarthy, MD
Family Medicine · Waycross, GANPI 1578827408
Payments from drug & device makers
Across 291 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$635
- Amgen$419
- GSK$379
- AbbVie$371
- AstraZeneca$347
- Pfizer$304
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,56298%
- Education$712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $635 |
| Amgen | 28 | $419 |
| GSK | 30 | $379 |
| AbbVie(2 entities) | 25 | $371 |
| AstraZeneca | 18 | $347 |
| Pfizer | 19 | $304 |
| Astellas Pharma US Inc | 14 | $272 |
| Lilly USA, LLC | 13 | $225 |
| Boehringer Ingelheim | 13 | $203 |
| Merz North America, Inc. | 1 | $175 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $142 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $110 |
| Antares Pharma, Inc. | 5 | $91 |
| Merck | 7 | $82 |
| Boston Scientific | 3 | $75 |
| Genentech USA, Inc. | 5 | $74 |
| Johnson & Johnson | 5 | $73 |
| Paratek Pharmaceuticals, Inc. | 4 | $72 |
| Bayer | 3 | $60 |
| Organogenesis Inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $49 |
| Idorsia Pharmaceuticals US Inc | 2 | $49 |
| Philips North America LLC | 1 | $39 |
| Exact Sciences | 1 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Ironshore Pharmaceuticals Inc. | 1 | $25 |
| Novartis | 2 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Almatica Pharma LLC | 1 | $19 |
| Indivior Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$4,633 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $145,207 |
| EliquisApixaban | 438 | $132,632 |
| JardianceEmpagliflozin | 226 | $118,364 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $65,837 |
| TrulicityDulaglutide | 68 | $60,142 |
| JanuviaSitagliptin Phosphate | 171 | $49,257 |
| MounjaroTirzepatide | 34 | $43,302 |
| LinzessLinaclotide | 53 | $42,421 |
| FarxigaDapagliflozin Propanediol | 122 | $38,916 |
| CreonLipase/Protease/Amylase | 21 | $27,476 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $25,938 |
| MyrbetriqMirabegron | 158 | $25,747 |
| RybelsusSemaglutide | 18 | $19,264 |
| EntrestoSacubitril/Valsartan | 36 | $19,134 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 154 | $18,941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $635 | $164,470117 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $203 | $140,702297 claims |
| PfizerEliquis | $304 | $132,632438 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $225 | $103,444102 claims |
| AbbVieLinzess, Creon, Vraylar, Namzaric, Savella | $371 | $99,577183 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $379 | $78,695135 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $347 | $59,290155 claims |
| MerckJanuvia, Janumet | $82 | $56,134208 claims |
| Astellas Pharma US IncMyrbetriq | $272 | $25,747158 claims |
| NovartisEntresto | $23 | $19,13436 claims |
| Johnson & JohnsonXarelto, Invokana | $73 | $14,97253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Waycross
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.